Navigation Links
Cadence Pharmaceuticals to Host Analyst and Investor Day
Date:11/28/2012

SAN DIEGO, Nov. 28, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company will host an Analyst and Investor Day for financial analysts on Thursday, December 6, 2012, from 9:00 am to 12:00 pm EST in New York, NY. Members of the Cadence senior management team will provide an update on the OFIRMEV® (acetaminophen) injection launch, as well as the Company's operations and business development plans. In addition, there will be two presentations by outside experts discussing their experience with OFIRMEV.

  • David J. Cziperle, M.D., FACS, Clinical Assistant Professor Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Director Thoracic and Cardiovascular Surgery Silver Cross Hospital
  • John Marshall, PharmD, BCPS, Clinical Coordinator – Critical Care, Beth Israel Deaconess Medical Center
  • Presentations will begin at 9:00 am EST.  For additional information and registration, please e-mail cadence@westwicke.com, or call 858-356-5930.

    A live webcast of the event will be accessible from the Company's website at investors.cadencepharm.com. Please allow extra time prior to the webcast to visit the site and download any streaming media software that may be required to listen to the broadcast. The event will be archived on the Company web site for 90 days.

    About OFIRMEV® (Acetaminophen) Injection
    OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

    Important Safety Information
    Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

    For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

    About Cadence Pharmaceuticals, Inc.
    Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com under "Events and Presentations."

    Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.

     Contact:

    William R. LaRueSVP, CFOCadence Pharmaceuticals, Inc.858-436-1400


    '/>"/>
    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cadence to Open Finished Medical Device Facility
    2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
    3. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    5. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    6. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
    7. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
    8. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    9. Nobel Prize Winner Bruce Beutler joins Sound Pharmaceuticals
    10. Valeant Pharmaceuticals Announces New Management Appointments
    11. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
    (Date:5/2/2016)... -- Kalorama Information noted the 5 Most Important Trends ... recent white paper.  The healthcare market research publisher said ... market are among the top drivers of market growth. ... EMR 2016: The Market for Electronic Medical Records ... the EMR industry, and the report is consulted by ...
    (Date:5/2/2016)... 2016 The global  ultrasound ... billion by 2024, according to a new report ... of the sonography market include expanding applications of ... for periodic ultrasound screenings of the breast for ... ) High Intensity Focused Ultrasound ...
    Breaking Medicine Technology:
    (Date:5/4/2016)... Carlsbad, CA (PRWEB) , ... May 04, 2016 , ... ... has recently partnered with local company MitoXcell in preparation of the launch of her ... day jump start plan is a nutritional guide designed to jump start a new ...
    (Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
    (Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
    (Date:5/4/2016)... ... May 04, 2016 , ... ... and support for knees, ankles, and elbows. Engineered with athletes in mind, ... flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) produces ...
    (Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
    Breaking Medicine News(10 mins):